Abstract
The use of umbilical or placental donor cord blood transplantation (CBT) in children with malignant and non-malignant diseases has witnessed important progress, mainly because of better cord blood donor choice and patient selection translating into better patient outcome. Approximately 2000 children with malignant diseases (about 75 % with acute leukemias) have been transplanted with a related (n=199) or unrelated CBT (UCBT, n=1663) and reported to Eurocord registry from 1990–2008. Disease-specific studies have been carried out after UCBT for acute lymphoblastic and myeloid leukemia and myelodysplastic syndromes in others to identify the risk factors that may improve outcomes. Outcomes after CBT have been compared with other alternative allogeneic hematopoietic SCT (HSCT) donors. Briefly, after CBT, myeloid engraftment is delayed, acute and chronic GVHD decreased and disease-free survival was not statistically different when compared with HLA identical and other alternative HSCT donor. Therefore, any physician has to carefully evaluate, for each single pediatric patient in need of an allograft, all the possible alternatives in order to choose the best hematopoietic stem cell donor, taking into account type of disease, urgency of transplantation, donor characteristics and center experience. This review will analyze the current results of CBT for pediatric patients with malignant diseases and the advantages and limitations of using this stem cell source.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gluckman E, Broxmeyer HE, Auerbach AD, Friedman HS, Douglas GW, Devergie A et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989; 321: 1174–1178.
Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R et al. Outcome of cord blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337: 373–381.
Rocha V, Chastang C, Souillet G, Pasquini R, Plouvier E, Nagler A et al. Related cord blood transplants: the Eurocord experience from 78 transplants. Eurocord Transplant Group. Bone Marrow Transplant 1998; 21: S59–S62.
Locatelli F, Rocha V, Chastang C, Arcese W, Michel G, Abecasis M et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 1999; 93: 3662–3671.
Locatelli F, Rocha V, Reed W, Bernaudin F, Ertem M, Grafakos S et al. Related umbilical cord blood transplant in patients with thalassemia and sickle cell disease. Blood 2003; 101: 2137–2143.
Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565–1577.
Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611–1618.
Rocha V, Wagner JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM et al. Graft-versus-host disease in children who have received a cord blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med 2000; 342: 1846–1854.
Rocha V, Cornish J, Sievers E, Filipovich A, Locatelli F, Peters C et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962–2971.
Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE . Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97: 2957–2961.
Dalle JH, Duval M, Moghrabi A, Wagner JE, Vachon MF, Barrette S et al. Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow. Bone Marrow Transplant 2004; 33: 605–611.
Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369: 1947–1954.
Michel G, Rocha V, Chevret S, Arcese W, Chan KW, Filipovich A et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord group analysis. Blood 2003; 102: 4290–4297.
Reed W, Smith R, Dekovic F, Lee JY, Saba JD, Trachtenberg E et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. Blood 2003; 101: 351–357.
Kurtzberg J, Prasad VK, Carter SL, Wagner JE, Baxter-Lowe LA, Wall D et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008; 112: 4318–4327.
Rocha V, Locatelli F . Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant 2008; 41: 207–214.
Locatelli F, Zecca M, Pession A, Maserati E, De Stefano P, Severi F . Myelodysplastic syndromes: the pediatric point of view. Haematologica 1995; 80: 268–279.
Hasle H. Myelodysplastic and myeloproliferative disorders in children. Curr Opin Pediatr 2007; 9: 1–8.
Locatelli F, Zecca M, Niemeyer C, Angelucci E, Arceses G, Bender-Gotze C et al. Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood. The European Working Group on Childhood Myelodysplastic Syndrome (EWOG-MDS) and the Austria-Germany-Italy (AGI) Bone Marrow Transplantation Registry. Bone Marrow Transplant 1996; 18: 63–68.
Webb DK, Passmore SJ, Hann IM, Harrison G, Wheatley K, Chessells JM . Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99. Br J Haematol 2002; 117: 33–39.
Barker JN, Krepski TP, DeFor T, Davies SM, Wagner JE, Weisdorf DJ . Searching for unrelated donor hematopoietic stem cell grafts: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002; 8: 257–260.
Davey S, Armitage S, Rocha V, Garnier F, Brown J, Brown CJ et al. The London Cord Blood Bank: analysis of banking and transplantation outcome. Br J Haematol 2004; 125: 358–365.
Hwang WY, Samuel M, Tan D, Koh LP, Lim W, Linn YC . A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant 2007; 13: 444–453.
Rocha V, Gluckman E . Outcomes of transplantation in children with acute leukaemia. Lancet 2007; 369: 1906–1908.
Hough R, Labopin M, Michel G, Locatelli F, Klingebiel T, Arcese W et al. Outcomes of fully haplo-identical haematopoietic stem cell transplantation compared to unrelated cord blood transplantation in children with acute lymphoblastic leukaemia. A retrospective analysis on behalf of Eurocord, PDWP and ALWP of EBMT. Bone Marrow Transplant 2007; 39: S3.
Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW et al. Eurocord Group. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32: 397–407.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rocha, V., Kabbara, N., Ionescu, I. et al. Pediatric related and unrelated cord blood transplantation for malignant diseases. Bone Marrow Transplant 44, 653–659 (2009). https://doi.org/10.1038/bmt.2009.291
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.291
Keywords
This article is cited by
-
Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study
International Journal of Hematology (2021)
-
Comparison of clinical outcomes between unrelated single umbilical cord blood and “ex-vivo” T-cell depleted haploidentical transplantation in children with hematological malignancies
World Journal of Pediatrics (2021)
-
Cord blood research, banking, and transplantation: achievements, challenges, and perspectives
Bone Marrow Transplantation (2020)
-
Improved outcomes of allogeneic hematopoietic stem cell transplantation including haploidentical transplantation for childhood myelodysplastic syndrome
Bone Marrow Transplantation (2020)
-
Long-term outcome and prognostic factors of unrelated cord blood transplantation in children with haematological malignancies: a retrospective study using the Spanish Working Party for BMT in Children (GETMON) database
Bone Marrow Transplantation (2014)